Bone Therapeutics to host Annual General Meeting and Extraordinary General Meeting on 8 June 2022
09 Maio 2022 - 2:00AM
Bone Therapeutics to host Annual General Meeting and Extraordinary
General Meeting on 8 June 2022
REGULATED INFORMATION
Preliminary documents for the Annual and
Extraordinary General Meeting have been made available on company’s
website
Mont-Saint-Guibert,
Belgium,
9 May
2022, 7am
CEST – BONE THERAPEUTICS
(Euronext Brussels and Paris: BOTHE), the cell therapy company
addressing unmet medical needs in orthopedics, invites its
shareholders and the holders of registered subscription rights and
registered convertible bonds of the Company to the Annual General
Meeting to be held on Wednesday 8 June 2022 as from 4:00 pm CEST,
at Rue Granbonpré 11, Building H, 1435 Mont-Saint-Guibert,
Belgium.
Bone Therapeutics also invites its shareholders
and the holders of registered subscription rights and registered
convertible bonds of the Company to the extraordinary general
meeting which will be held on the same day as from 6:00 pm
CEST, at Rue du Fort 24, 6000 Charleroi, Belgium. If the quorum is
not reached at this extraordinary general meeting, a second
extraordinary general meeting will be convened and held on 27 June
2022 from 11:00 am, at Rue du Fort 24, 6000 Charleroi, Belgium.
The notices for the meetings, including the
agenda of the day as well as the motions to vote, are published
today in the Belgian Official Gazette and La Libre Belgique.
The documents and preliminary information
concerning these meetings have been made available and can be
consulted on Bone Therapeutics’ website, under the section
Investors / Shareholders’ meeting, in compliance with the
applicable law and regulations.
It is also possible to receive the documents
without charge upon simple request by email to
generalassembly@bonetherapeutics.com or by telephone on +32 (0)493
09 73 66. The documents are also available at the Company’s
headquarters, Rue Granbonpré 11, Building H, 1435 Mont-St-Guibert,
Belgium.
About Bone Therapeutics
Bone Therapeutics is a leading biotech company
focused on the development of innovative products to address high
unmet needs in orthopedics and other diseases. Currently Bone
Therapeutics is concentrating specifically on the development of
its most advanced clinical asset, the allogeneic cell therapy
platform, ALLOB.
Bone Therapeutics’ core technology is based on
its cutting-edge allogeneic cell and gene therapy platform with
differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs)
which can be stored at the point of use in the hospital. Its
leading investigational medicinal product, ALLOB, represents a
unique, proprietary approach to bone regeneration, which turns
undifferentiated stromal cells from healthy donors into
bone-forming cells. These cells are produced via the Bone
Therapeutics’ scalable manufacturing process. Following the CTA
approval by regulatory authorities in Europe, the Company has
initiated patient recruitment for the Phase IIb clinical trial with
ALLOB in patients with difficult tibial fractures, using its
optimized production process. ALLOB continues to be evaluated for
other orthopedic indications including spinal fusion, osteotomy,
maxillofacial and dental.
Bone Therapeutics’ cell therapy products are
manufactured to the highest GMP (Good Manufacturing Practices)
standards and are protected by a broad IP (Intellectual Property)
portfolio covering ten patent families as well as knowhow. The
Company is based in the Louvain-la-Neuve Science Park in
Mont-Saint-Guibert, Belgium. Further information is available at
www.bonetherapeutics.com.
For further information, please
contact:
Bone Therapeutics SAMiguel
Forte, MD, PhD, Chief Executive OfficerTel: +32 (0)493 09 73
66investorrelations@bonetherapeutics.com
For Belgian Media and Investor
Enquiries:BepublicBert BouserieTel: +32 (0)488 40
44 77bert.bouserie@bepublicgroup.be
International Media Enquiries:Image Box
CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20
8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Media and Investor
Enquiries:NewCap Investor Relations &
Financial CommunicationsPierre Laurent, Louis-Victor
Delouvrier and Arthur RouilléTel: +33 (0)1 44 71 94
94bone@newcap.eu
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company or, as
appropriate, the Company directors’ current expectations and
projections about future events. By their nature, forward-looking
statements involve a number of risks, uncertainties and assumptions
that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, competition and technology, can cause actual
events, performance or results to differ significantly from any
anticipated development. Forward looking statements contained in
this press release regarding past trends or activities should not
be taken as a representation that such trends or activities will
continue in the future. As a result, the Company expressly
disclaims any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither the Company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.